Myeloproliferative Disorders
17 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Hematologic Diseases
Narrower: Primary Myelofibrosis 10, Thrombocythemia, Essential 3
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Azacitidine + Ascorbic Acid for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezuclastinib for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Givinostat for primary myelofibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Givinostat for thrombocythemia, essential | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Luspatercept for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Navitoclax for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peginterferon α-2b injection for thrombocythemia, essential | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pelabresib for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROPEGINTERFERON ALFA-2B for thrombocythemia, essential | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxolitinib + NAVITOCLAX for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selinexor for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tasquinimod for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TASQUINIMOD + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ULIXERTINIB + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.